entertainment -WSS

entertainment

author：explore 2025-08-28 13:04:11 - browse：29979

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

WSS

What is STAT's opinion section for?

Publishing genetic code of viruses could cause disaster

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Hundreds died while taking an arthritis drug, but nobody alerted patients

Scientific mystery highlights the blind spots in genomics databases

explore

entertainment

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA reorg will put new emphasis on investigations, sources say

Supreme Court strikes down use of affirmative action

Trial using CRISPR to edit HIV out of cells disappoints

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Duchenne breakthrough therapy leaves behind pioneering families

Four alarming medical procedures we’re glad history forgot

hotspot

Study suggests Covid rebound is far more common with Paxlovid than without

Trial using CRISPR to edit HIV out of cells disappoints

Carbon Health diabetes program, a test of data

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

leisure time

focus

hotspot

Wikipedia